SEC Form 4 · accession 0001209191-15-003387
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Jan 7, 2015
Accepted (ET)
Jan 9, 2015 · 4:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 7, 2015 | M | 4,800 | $10.41 | A | 343,695 | D | |
| Common Stock | Jan 7, 2015 | M | 1,300 | $17.16 | A | 344,995 | D | |
| Common Stock | Jan 7, 2015 | M | 4,400 | $35.64 | A | 349,395 | D | |
| Common StockF2,F3 | Jan 7, 2015 | S | 3,500 | $118.69 | D | 345,895 | D | |
| Common StockF3,F4 | Jan 7, 2015 | S | 4,800 | $119.35 | D | 341,095 | D | |
| Common StockF3,F5 | Jan 7, 2015 | S | 2,200 | $120.26 | D | 338,895 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common StockF6 | holding | — | — | — | 172,589 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $10.41 | Jan 7, 2015 | M | 4,800 | D | — | Feb 2, 2015 | Common Stock | 4,800 | 14,588 | D |
| Stock Option (right to buy)F7 | $17.16 | Jan 7, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 35,600 | D |
| Stock Option (right to buy)F7 | $35.64 | Jan 7, 2015 | M | 4,400 | D | — | Feb 1, 2016 | Common Stock | 4,400 | 542,800 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $118.69 (range $118.00 to $118.98).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $119.35 (range $119.01 to $119.96).
- F5Open market sales reported on this line occurred at a weighted average price of $120.26 (range $120.02 to $120.51).
- F6Common stock held in grantor retained annuity trusts.
- F7Fully vested.